2.625
price down icon0.94%   -0.025
 
loading
Aytu Biopharma Inc stock is traded at $2.625, with a volume of 121.07K. It is down -0.94% in the last 24 hours and up +22.09% over the past month. Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
See More
Previous Close:
$2.65
Open:
$2.65
24h Volume:
121.07K
Relative Volume:
0.09
Market Cap:
$23.56M
Revenue:
$93.76M
Net Income/Loss:
$-13.68M
P/E Ratio:
-0.9981
EPS:
-2.63
Net Cash Flow:
$8.77M
1W Performance:
+10.76%
1M Performance:
+22.09%
6M Performance:
+54.41%
1Y Performance:
-2.78%
1-Day Range:
Value
$2.55
$2.70
1-Week Range:
Value
$2.32
$2.70
52-Week Range:
Value
$0.95
$2.85

Aytu Biopharma Inc Stock (AYTU) Company Profile

Name
Name
Aytu Biopharma Inc
Name
Phone
(720) 437-6580
Name
Address
7900 E. UNION AVENUE, DENVER
Name
Employee
102
Name
Twitter
@aytubioscience
Name
Next Earnings Date
2024-12-13
Name
Latest SEC Filings
Name
AYTU's Discussions on Twitter

Compare AYTU with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
AYTU
Aytu Biopharma Inc
2.625 23.79M 93.76M -13.68M 8.77M -2.63
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
152.12 68.04B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.48 46.30B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.88 44.25B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.54 18.73B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
304.50 13.82B 2.99B 1.21B 1.13B 25.06

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-01-25 Initiated Lake Street Buy
Jun-30-25 Initiated Ascendiant Capital Markets Buy
Mar-30-21 Initiated Cantor Fitzgerald Overweight
May-29-20 Initiated H.C. Wainwright Buy

Aytu Biopharma Inc Stock (AYTU) Latest News

pulisher
Jul 25, 2025

What analysts say about Aytu BioPharma Inc. stockDynamic profit opportunities - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

What risks could impact Aytu BioPharma Inc. stock performanceHigh-velocity capital appreciation - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Aytu BioPharma Inc. stock priceExplosive trading growth - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Aytu BioPharma Inc. Stock Analysis and ForecastPhenomenal trading returns - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

What analysts say about Aytu BioPharma Inc. stock outlookJaw-dropping returns - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 22, 2025

Is Aytu BioPharma Inc. a good long term investmentConsistent high-performance stocks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

11 Best High Return Penny Stocks to Buy Now - Insider Monkey

Jul 21, 2025
pulisher
Jul 17, 2025

What makes Aytu BioPharma Inc. stock price move sharplyWeekly Big Movers - beatles.ru

Jul 17, 2025
pulisher
Jul 16, 2025

Why Aytu BioPharma Inc. stock attracts strong analyst attentionDouble Profit With Half Risk - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

How Aytu BioPharma Inc. stock performs during market volatilityTrending Stock Alert - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

Aytu BioPharma Completes $15 Million Debt Refinancing - ACCESS Newswire

Jul 12, 2025
pulisher
Jul 05, 2025

Aytu BioPharma (NASDAQ:AYTU) Downgraded by Wall Street Zen to Buy - Defense World

Jul 05, 2025
pulisher
Jul 04, 2025

Aytu Boosts Liquidity with Eclipse Loan Extension - MSN

Jul 04, 2025
pulisher
Jul 02, 2025

Aytu BioPharma (NASDAQ:AYTU) Now Covered by Lake Street Capital - Defense World

Jul 02, 2025
pulisher
Jul 01, 2025

Aytu BioPharma (AYTU): Lake Street Initiates Coverage with Buy Rating | AYTU Stock News - GuruFocus

Jul 01, 2025
pulisher
Jul 01, 2025

Lake Street Initiates Aytu BioPharma at Buy With $8 Price Target - MarketScreener

Jul 01, 2025
pulisher
Jul 01, 2025

Aytu BioPharma (NASDAQ:AYTU) Coverage Initiated by Analysts at Ascendiant Capital Markets - Defense World

Jul 01, 2025
pulisher
Jun 30, 2025

AYTU: Ascendiant Capital Initiates Coverage with 'Buy' Rating | AYTU Stock News - GuruFocus

Jun 30, 2025
pulisher
Jun 30, 2025

This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Jun 30, 2025
pulisher
Jun 30, 2025

Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire

Jun 30, 2025
pulisher
Jun 28, 2025

AYTU SEC FilingsAytu Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 28, 2025
pulisher
Jun 28, 2025

Aytu BioPharma (NASDAQ:AYTU) Upgraded by Wall Street Zen to Strong-Buy Rating - Defense World

Jun 28, 2025
pulisher
Jun 26, 2025

15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey

Jun 26, 2025
pulisher
Jun 25, 2025

Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM) - ACCESS Newswire

Jun 25, 2025
pulisher
Jun 23, 2025

Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) - ACCESS Newswire

Jun 23, 2025
pulisher
Jun 23, 2025

Aytu BioScience Expands Lending Agreement for EXXUA Launch - TipRanks

Jun 23, 2025

Aytu Biopharma Inc Stock (AYTU) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Aytu Biopharma Inc Stock (AYTU) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Disbrow Joshua R.
Chief Executive Officer
Jun 09 '25
Buy
1.50
66,666
99,999
153,257
Disbrow Joshua R.
Chief Executive Officer
Feb 28 '25
Buy
1.30
15,000
19,500
86,591
$72.93
price up icon 2.82%
$14.92
price up icon 1.57%
$9.41
price up icon 0.64%
drug_manufacturers_specialty_generic RDY
$14.67
price down icon 0.27%
$132.14
price up icon 0.38%
$304.50
price down icon 0.62%
Cap:     |  Volume (24h):